Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6404MR)

This product GTTS-WQ6404MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6404MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6985MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ125MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ1430MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ14020MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ13155MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ9251MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ10536MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ5728MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW